Luigi Pinna

Dr. Luigi Pinna

orcid

Research Focus & Metrics

Academic Career Length

64Years (1963-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1990 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
LPLuigi Pinna
Luigi Pinna

1 December 1996 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
LPLuigi Pinna
Luigi Pinna
Maria RuzzeneMaria Ruzzene
Maria Ruzzene

1 June 2015 in Cell
Verified
Journal Article
Closed access
VTVincent S. Tagliabracci
Vincent S. Tagliabracci
SWSandra E. Wiley
Sandra E. Wiley
XGXiao Guo
Xiao Guo
LKLisa N. Kinch
Lisa N. Kinch
EDEric Durrant
Eric Durrant
JDJack E. Dixon
Jack E. Dixon

1 March 2010 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
LPLuigi Pinna
Luigi Pinna

15 October 2008 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
MPMario Pagano
Mario Pagano
JBJenny Bain
Jenny Bain
ZKZygmunt Kazimierczuk
Zygmunt Kazimierczuk
SSStefania Sarno
Stefania Sarno
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
LPLuigi Pinna
Luigi Pinna
CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathological conditions with special reference to neoplasia. The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. In the present study we show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compound TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a). In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. In an attempt to improve selectivity towards CK2 a library of 68 TBB/TBI-related compounds have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compounds whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase. Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.

8 May 2002 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
DPDaniele Penzo
Daniele Penzo
LPLuigi Pinna
Luigi Pinna
Incubation of Jurkat cells with 4,5,6,7-tetrabromobenzotriazole (TBB), a specific inhibitor of protein kinase CK2, induces dose-and time-dependent apoptosis as judged by several criteria. TBB-promoted apoptosis is preceded by inhibition of Ser/Thr phosphorylation of haematopoietic lineage cell-specific protein 1 (HS1) and is accompanied by caspase-dependent fragmentation of the same protein. Both effects are also observable if apoptosis is promoted by anti-Fas antibodies and by etoposide. Moreover, in vitro experiments show that HS1, once phosphorylated by CK2, becomes refractory to cleavage by caspase-3. These findings, in conjunction with similar data in the literature concerning two other CK2 protein substrates, Bid and Max, suggest that CK2 may play a general anti-apoptotic role through the generation of phosphorylated sites conferring resistance to caspase cleavage.